Bio Search Signs Deal for Full Ownership of Brain-AI Firm

By James Calloway

Japan's Bio Search signed a share-exchange agreement on November 9, 2026, to acquire 100% of InnerEye, an Israeli company developing AI that analyzes brain signals in real time. Bio Search said the transaction would make InnerEye a wholly owned subsidiary and add its expert-decision technology to its healthcare AI business.

Completion has not occurred. Bio Search scheduled the closing for between December 2026 and early January 2027, subject to customary conditions, including approvals from relevant Israeli authorities.

What does the share exchange cover?

Bio Search's agreement covers 100% of InnerEye. If the closing occurs, InnerEye would become a wholly owned subsidiary with its expert-decision technology inside Bio Search's healthcare AI operation.

The announcement does not disclose the transaction value, exchange ratio, revenue forecast, expected earnings contribution, or post-closing funding plan. It also leaves the relevant Israeli authorities unnamed and does not describe the approval process.

Those omissions limit any assessment of execution risk, financing needs, and the regulatory timetable. Completion still requires the customary conditions Bio Search listed, including approvals from relevant Israeli authorities. The announced window between December 2026 and early January 2027 remains conditional rather than a guaranteed closing date.

Takeaway: The signed agreement covers 100% ownership, but the price, finances, and approval path remain undisclosed.

Why does Bio Search want InnerEye?

The deal gives Bio Search a route from biological sensors into decision-support software. Bio Search already uses electroencephalogram (EEG, a recording of brain electrical activity), electrocardiogram (ECG, a recording of heart electrical activity), heart-rate and electromyography (EMG, a recording of muscle electrical activity) signals in healthcare AI.

Bio Search's existing operations span biological sensing, medical-device engineering, and business development in Japan and other Asian markets. Pairing those capabilities with InnerEye's software would connect signal capture and device design with models of expert judgment.

Takeaway: InnerEye would give Bio Search's sensor business a software layer for reproducing and assessing human decisions.

How does InnerEye encode expert judgment?

InnerEye's product documentation describes Minded A.I. as a workflow for transferring aspects of expert judgment into AI models. An expert wears a device that serves as the interface, while the system converts elements of that person's decisions into digital insights.

Those insights teach models to reproduce expert decision patterns. The documentation also says they support assessments of user performance and trust in the expert's decisions.

InnerEye describes a continuing feedback loop intended to improve both the models and the expert users. Its two named products put that mentoring process to different uses:

• Sense.I applies the mentoring process to AI training, personalization, and optimization.
• SensePlus focuses on the cognitive and emotional factors behind actions. Its functions detect fatigue, concentration, and attention levels during tasks to help reduce human error.

These capabilities describe intended functions, not demonstrated outcomes. The announcement gives no accuracy rate, error rate, study size, customer deployment, or independent evaluation of the mentoring loop.

Takeaway: Minded A.I. offers a plausible way to encode judgment, but the announcement supplies no evidence that it reproduces expert decisions reliably.

What can the EEG system actually measure?

Bio Search says InnerEye's proprietary algorithms interpret EEG readings in real time to distinguish cognitive states involved in perception and decision-making. That real-time classification would support both the Sense.I mentoring workflow and the SensePlus assessment functions.

InnerEye was founded in 2014 by Amir Geva, a professor of electrical and computer engineering at Ben-Gurion University of the Negev, and Leon Deouell, a physician and professor of brain sciences at the Hebrew University of Jerusalem.

The founders' combined research underpins technology designed to learn decision processes rooted in personal experience and tacit knowledge, meaning knowledge that is difficult to codify, before deploying trained models. Bio Search presents this research history as the foundation for InnerEye's expert-decision approach.

The announcement supplies no benchmark numbers for signal classification, accuracy, false positives, task performance, or response latency. It also names no hardware specifications, independent studies, clinical cohorts, or customer deployments. Without those measures, the “real time” and “expert decision” claims remain difficult to test against any benchmark.

Takeaway: The EEG approach rests on documented founder expertise, but neither clinical validation nor comparative performance appears in the announcement.

How would Bio Search integrate the two companies?

At the center of the integration plan is a shared platform for pooling both companies' EEG and other biological data to train AI models. The platform would connect Bio Search's existing sensor and device engineering with InnerEye's expert-judgment software.

Bio Search projects improvements in precision, robustness, and analytical scope, although it gives no numerical targets or test conditions. Robustness, meaning stable performance when inputs or conditions change, receives no reported test in the announcement. The company also does not say how much the pooled data would improve InnerEye's models or Bio Search's existing healthcare systems.

Bio Search names six broad target uses:

• Visualizing cognitive function
• Supporting early diagnosis
• Industrial automation
• Affective computing, meaning systems that infer or respond to emotional and cognitive states
• Security
• Decision support for experts

The announcement names no disease for early diagnosis, clinical setting, patient population, or clinical endpoint. It also identifies no industrial task, security use case, customer, hardware specification, or paid deployment. Nor does it describe consent, data retention, security controls, or ownership of pooled biological data.

Takeaway: The proposed data platform spans medicine and industry, but neither its promised gains nor the evidence required for those uses has been defined.

How far does the commercial plan go?

Beyond technical integration, the companies plan a unified executive structure across Japan and Israel. They also plan stronger governance and internal controls.

Bio Search has set a target of a Nasdaq listing in 2028. The announcement does not lay out milestones, required capital, or a link between closing the InnerEye deal and meeting the listing timetable.

InnerEye CEO Uri Antman described the combination as “the ideal partnership to elevate the Brain-AI technology we have cultivated over many years into a global commercial scale.” The statement expresses commercial ambition, but the announcement offers no revenue, subscriber, deployment, or market-size figures against which to test that scale.

Bio Search also does not disclose InnerEye's revenue, customer count, model performance, or commercial timetable. Its purchase therefore combines a signed agreement and a stated integration plan with limited public evidence of operating scale.

Takeaway: The management plan is concrete, but the 2028 listing target rests on commercial and technical milestones the announcement does not define.

What must happen before this becomes real?

Regulatory approval and closing are the immediate requirements. Until completion, the announced 100% ownership transfer has not taken effect. Bio Search describes the shared platform and unified management structure as future plans.

The longer-term test is whether pooling brain and other biological data can produce models reliable enough for the broad healthcare and industrial uses Bio Search has identified. The 2028 Nasdaq target gives that technical and commercial question a concrete operational test, even though the announcement leaves the required evidence unspecified.

Bio Search must still clear the approval process, complete the exchange, integrate teams and systems across Japan and Israel, and show that the combined platform improves performance in actual use. Any one of those steps could change the path or timing the company has described.

Takeaway: Bio Search's 2028 Nasdaq goal now depends on regulatory clearance, working cross-border integration, and reliable models in the healthcare and industrial uses it has named.